Rankings
▼
Calendar
TARS Q2 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
Q2 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
-$316,000
Operating Income
-$33M
Net Income
-$31M
EPS (Diluted)
$-1.17
QoQ Revenue Growth
-100.0%
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$25M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$189M
Total Liabilities
$41M
Stockholders' Equity
$148M
Cash & Equivalents
$107M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$15M
-100.0%
Gross Profit
-$316,000
$15M
-102.1%
Operating Income
-$33M
-$5M
-528.3%
Net Income
-$31M
-$6M
-447.2%
← FY 2023
All Quarters
Q3 2023 →